Replies to post #153220 on Enzolytics Inc (ENZC)

[MAGA_PATRIOT]

As real as it gets CassieW, and current pps takes the word "undervalued" to entirely new level.... Plenty of dd on this board, twitter, and discord to occupy you for the next week...

$ENZC

[makindatcash]

As real as it gets..

[Jeff Taitano]

There's a lot to read through if you're into the fundamentals and filings. Read it all - the good and the bad. Through all of it there is a steady group of longs that believe in the company and what they're doing. Lots coming up, but it's biotech so keep any timelines in reality and just enjoy the ride if you jump on board. You'll see a lot of opinions going to both extremes, bearish and bullish, but the reality is likely somewhere in-between. My crazy opinion - we're about to see what they've been working on behind the scenes, animal study announcements imminent.

[foxi]

I recommend doing some digging on these boards and elsewhere for better DD, and don't just take our word for it! IMO it's worth getting to know ENZC if you spend a lot of time trading pinks.

This looks like a real company to me, with some truly disruptive medicine in the works -- that is also prone to pumps and dumps. Some of the P&D's may be orchestrated by ENZC itself, and a lot seems to be Twitter traders & the market taking advantage of ENZC's long-play roadmap, weak communication and inexperienced management.

The company has a paid hype guy with a track record of pumping shadier stocks. They've also chronically promised stuff that they don't deliver, such as an audit & uplist and a dietary supplement that would hopefully bring the company's first recurring revenue. Whenever there's bad news they have a history of going radio silent and investors find out weeks or months later. There are many bagholders and many would rush to get out if they could ever break even.

ENZC has an ongoing drug manufacturing partnership with Samsung (for upcoming clinical trials) and once co-authored a whitepaper on AI-driven medicine with Intel. These are unusual affiliations for an OTC pink. ENZC has two very exciting technologies that are steadily maturing: monoclonal antibodies that have been greatly improved with AI analysis to target something like 20+ well known and major human illnesses, and another dozen-ish animal illnesses; and a drug called ITV-1 that shows promise in treating HIV and covid. The mAbs are patent pending and ITV-1 is already patented.

ENZC is currently under a NDA for some reason, and nobody knows why, hence the uptick in speculative hype on social media of things like a buyout or Big Pharma partnership. A slew of major deliverables are currently overdue and there are rumblings that in the next couple months things might finally begin coming to fruition. Expect to see more Twitter buzz in the weeks ahead and keep this on your watch list in case they get a surprise catalyst. GLTY